Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
|Videos|March 31, 2022
Lupus Treatment Advances: Advice to Colleagues
Advice to rheumatologists in terms of staying up to date on newer treatment options entering the market for lupus.
Advertisement
Advertisement
Related to this article
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline
2
Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD
3
Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD
4
INDIGO: Obexelimab Sustains IgG4-RD Flare Control, With John Stone, MD, MPH
5